hotspot -WSS

hotspot

author：entertainment 2025-09-29 21:22:56 - browse：6372

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： What happened to the House vote on health price transparency?

focus

WSS

Why the drug industry's warnings on the IRA's impact fall short

'A game

Weight loss drugs should be covered by insurers, AMA says

House panel takes first step toward fixing drug shortages

People with substance use disorder deserve online privacy

What health policies could hitch a ride on a spending bill?

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

Why the quest to eradicate polio has stumbled

Duchenne breakthrough therapy leaves behind pioneering families

How the messy conversation about Dolly changed bioethics

Continuity nursing helped my family in our darkest PICU moments

Fed up with FDA, ALS advocates consider a take

Dobbs anniversary: the lost opportunity of abortion as health care

'A game

Medical records are filled with copy

Study suggests Covid rebound is far more common with Paxlovid than without

hotspot

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Covid’s new normal has set in amid another rise in cases

Midwives could help bridge maternal health disparities in the U.S.

Ohio still needs to do more to protect the right to abortion

Akili changes sales model for its ADHD video game treatment

FDA reorg will put new emphasis on investigations, sources say

Wikipedia

focus

Wikipedia

hotspot